Isoflavone Mega
Natural health product licensed in Canada
- Licence holder
- Nature's Ace Biopharmaceutical Inc.
- NPN or DIN-HM
- 80076384
- Status
- Active licence
- Licence date
- 27 March 2017
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
- Conditions légales
Glycine max. (L.) Merr.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Glycine max Source : Graine(s) Potency : 15 Milligrammes d'équivalents aglycones d'isoflavones Genistein | Not specified | Not calculated |
| Glycine max Source : Graine(s) Potency : 22.5 Milligrammes d'équivalents aglycones d'isoflavones Soy isoflavone extract | 750 milligramme | Not calculated |
Non-medicinal ingredients
farine de riz, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes en postménopause | Not specified | 1 Capsule | 2 Tous les jours |
Uses authorised in Canada
May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats). Helps to attenuate/reduce bone mineral density loss in post-menopausal women when used in conjunction with adequate amounts of calcium and vitamin D.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Ensure you are up-to-date on mammograms and gynaecological evaluations prior to use. Consult a health care practitioner if symptoms worsen. Consult a health care practitioner prior to use if you are taking blood thinners. Consult a health care practitioner prior to use if you have a history of hormonal or gynaecological disease, including ovarian cancer. Consult a health care practitioner prior to use if you have a liver disorder or develop liver-related symptoms. Consult a health care practitioner prior to use if you are taking hormone replacement therapy, including thyroid hormone replacement therapy. Discontinue use and consult a health care practitioner if you experience breast pain, discomfort and/or tenderness, or if you experience a recurrence of menstruation and/or uterine spotting.
- Contre-indications
Do not use if you currently have or previously had breast cancer and/or breast tumours or if you have a predisposition to breast cancer, as indicated by an abnormal mammogram and/or biopsy, or a family member with breast cancer.
Source
Official Health Canada record, licence 80076384
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.